SCHEDULE: Armistice Capital Reports 4.99% Stake in Bicycle Therapeutics
Beneficial Ownership Report (Schedule 13G Amendment)
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Bicycle Therapeutics PLC.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates beneficial ownership of 359,703 American Depositary Shares of Bicycle Therapeutics PLC.
- This represents 4.99% of the class of securities.
- The shares are American Depositary Shares, each representing one ordinary share with a nominal value of 0.01 per share.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 359,703 shares.
- The filing was made pursuant to Rule 13d-1(b), typically used by institutional investors.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual report of beneficial ownership and does not inherently convey positive or negative sentiment about the company's operational or financial performance. It simply discloses an investor's stake.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing reflects a significant ownership stake by an institutional investor in a biotechnology company, which is a common occurrence in the investment landscape. It indicates Armistice Capital's continued or adjusted position in Bicycle Therapeutics PLC, a company likely focused on drug development or therapeutic research.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, informing them of a major investor's stake in the company.
- Investment Professionals: Offers insight into the holdings of Armistice Capital, LLC and Steven Boyd, which may influence investment decisions or analysis.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Bicycle Therapeutics PLC, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, ADS, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.